Experimental immunotherapy combo tested in advanced prostate cancer
NCT ID NCT05733351
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 40 times
Summary
This early-phase study tested whether adding the immunotherapy drug vudalimab (XmAb20717) to standard hormone therapy or chemotherapy could help men with prostate cancer that has spread. Only 4 men took part before the study was stopped. The main goals were to check safety and see if the combination slowed cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital Midtown
Atlanta, Georgia, 30308, United States
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.